Botensilimab

Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...

LEXINGTON, Mass., Aug. 26, 2026 Agenus Inc. announced updated results from the peer-reviewed Phase 2 NEST trial, providing longer...

LEXINGTON, Mass., August 6, 2026 Agenus Inc. reported its second-quarter 2026 financial results while outlining significant progress in advancing...

LEXINGTON, Mass., July 17, 2026 Agenus Inc. announced that three investigator-sponsored studies evaluating its investigational botensilimab plus balstilimab (BOT+BAL)...

LEXINGTON, Mass., July 6, 2026 Agenus announced new three-year follow-up results from the fully enrolled Phase 1b C-800-01 study...

LEXINGTON, Mass., April 3, 2026 Agenus Inc. has announced that new data from its Phase II clinical study evaluating...

LEXINGTON, Mass., Feb. 19, 2026 — Agenus Inc. announced new translational and clinical biomarker findings demonstrating survival stratification in...